Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01785615 · ClinicalTrials.gov registry record · Phase 1
Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT01785615 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 116 participants.
The verdict
NCT01785615, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
Little is known regarding the association of individual components of the metabolic syndrome (MBS) and prothrombotic, inflammatory and preclinical cardiac structural and functional markers in women with this syndrome. Less is known about adequate treatment as the pathological mechanism of this syndrome is not well understood. The purpose of this study is two fold; 1. To determine basic differences in biochemical and cardiovascular structural markers in women with and those without MBS and their association with the individual components of MBS. 2. To determine the impact of atorvastatin to lower the risk factors of Metabolic Syndrome. Atorvastatin is one of the most effective drugs approved by the United States Food and Drug Administration (FDA) for the treatment of high cholesterol. It belongs to a class of drugs called statins and its role in primary prevention is still unclear. Thus this population seems to be an ideal group that may benefit from this intervention.
Interventions
- OTHER Placebo
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2004-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01785615
The ClinicalTrials.gov registry entry for NCT01785615 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01785615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01785615 about?
NCT01785615 is a clinical study titled "Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin". Little is known regarding the association of individual components of the metabolic syndrome (MBS) and prothrombotic, inflammatory and preclinical cardiac structural and functional markers in women with this syndrome. Less is known about adequate treatment as the pathological mechanism of this syndr...
What is the current status of trial NCT01785615?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2004-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01785615?
The interventions under investigation include: Placebo (OTHER), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT01785615?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.